This week was quieter than the prior couple of weeks and the JPM Healthcare conference orbit, with the clearest signal being another “platform-first” pharma partnership: Alphabet-backed Isomorphic Labs teaming with Johnson & Johnson around AI-driven, multi-modality design, with a timeline update on Isomorphic’s first human trials of its own AI-designed …
Weekly Tech+Bio Highlights #70: Signals from a Quieter Week
Isomorphic Labs x J&J platform deal, LLM “gym” for pharma R&D, Absci’s new antibody model, and more
